Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Magnetic Resonance Technique Reveals Insights Into Lung Disease

By Drug Discovery Trends Editor | December 14, 2007

Doctors at the Universities of Nottingham and Leicester are collaborating in the use of a magnetic resonance technique to image and quantify the air spaces inside the lungs—and the results of their research may lead to a link between childhood disease and later degenerative lung disease. There are relatively few centres around the world which have access to this particular magnetic resonance technique, which is based at The University of Nottingham. Researchers at the University of Leicester have recruited a cohort of 10,000 children—the largest to focus on respiratory illnesses in childhood. The two research groups have combined forces, with a joint grant from the Wellcome Trust.

The method relies on the fact that certain noble gases, which are relatively rare in the atmosphere and are very un-reactive, can be detected by magnetic resonance methods when hyper-polarized in a very strong laser beam. Tests involve individuals inhaling a very small quantity—in this case 10ml or two teaspoons—of the hyperpolarized helium-3 gas. This technique provides the key to unlock a whole new area of research in the field of lung development.

This is quite different from the magnetic resonance scans that are now commonplace in British hospitals. However, all magnetic resonance techniques function without the use of radioactive substances or ionising radiation. They are thus very safe, have no known side effects and are ideal for research into childhood illness.

Release date: December 13, 2007
Source: The University of Nottingham


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50